创胜集团-B2025年中期报告

（以存續方式於開曼群島註冊的有限公司）股份代號 :6628 2025中期報告 245103355575860616284 Kumar Srinivasan •88135 Walkers Corporate Limited190 Elgin Avenue, George TownGrand Cayman KY1-9008Cayman Islands Kumar Srinivasan 218B6-501215123 Kumar Srinivasan 8240 33191928 Skadden, Arps, Slate, Meagher & Flom1542 Walkers Corporate Limited190 Elgin Avenue, George TownGrand Cayman, KY1-9008Cayman Islands 81111101-1104 1617 86/10/11/16/17 110 158 Walkers (Hong Kong)1815 6628 http://www.transcenta.com/ •20246 304.620256 302.7CDMO•20246 309.61.820256 3011.420256 30•20246 301.02.220256301.2•20246 30103.026.320256 3076.7•20246 3031.43.1202563028.3•20246 30135.226.420256 30108.8 •20246 304.620256 302.7CDMO•20246 309.61.820256 3011.420256 30•20246 3095.524.720256 3070.8•20246 3026.11.220256 3024.9•20246 30122.423.020256 3099.4 2025 Claudin18.2Osemitamab (TST001)Claudin18.26(ASCO)OsemitamabCAPOX(TranStar102)IIG26≥40%CLDN18.22+3+PD-L1 CPS(mPFS)16.6(mOS)21.7(FDA)(MFDS)III(TranStar301) FGFR2bLIV-1 TST105 TST01320254(AACR)FGFR2bADC(TST105)FGFR2bTST105MMAEADCFGFR2bTST801BAFFAPRILTST808 OsemitamabTST001ADCCClaudin18.2 •20253Claudin18.2 •20256Osemitamab (TST001)CAPOX(TranStar102)IIG#4032)2025ASCO2614G11 IHC LDTCLDN18.240%2+3+PDL1(mOS)21.7(mPFS)16.6(cORR)68%(mDoR)16.5 Osemitamab (TST001)CDx •CDxClaudin18.2(CDx)osemitamab (TST001)Claudin18.2TranStar301III TST786PD1-VEGFGREMLIN-1 TST786PD1-VEGFGREMLIN-1GREMLIN-1PD1-VEGFPFSOSPFSOS2025 TST105ADC •TST105FGFR2b(ADC)FGFR2bADC20254AACRTST105IMMAEADCAACRTST105FGFR2b TST013LIV-1ADC •TST013LIV-1ADCLIV-1ADCTOPO-IPKADCINDADCTST013 TST801 •TST801BAFFTACIBAFFAPRILTACIBBAFFAPRIL(SLE)(LN)IgA(IgAN)(gMG)TST801BINDBAFFTST801TST801BDNA (dsDNA)A (IgA)M (IgM)G (IgG) TST808B •TST808BTST808BTST808IgANIND •TranStar102TranStar101osemitamab (TST001)BMS•Claudin18.2CDxosemitamab (TST001)TranStar301III•osemitamab (TST001)•TST002TST801 TST808 TST105 TST013•20253 25HiCB•siRNAsiRNACDMO•ExcelPro CHOCHOExcelPro CHO CMCCDMO CMC •osemitamab (TST001)FDA Cosemitamab (TST001) •CDMO• CDMO •siRNA•• osemitamab (TST001)FDAMFDSosemitamab (TST001)Claudin18.2IIIClaudin18.2 CMCHiCBCMCCDMO 16blosozumab (TST002) PD-L1=1TGFβ=βMASP2=2IND=FIC=HPV=NSCLC=SLE=LN=TMA=IgA=AMono=Combo=Chemo=VEGFR2=2 (1)20219 14 (2) 16TST001TST002 TST004 TST801 TST808TST003TST786TST0082025 osemitamab (TST001)MSB0254TST003 TST105 TST012 TST013 •Osemitamab (TST001)Claudin18.2III(TranStar301)osemitamab (TST001)Claudin18.2FDAMFDSClaudin18.2•MSB0254VEGFR2•TST003GREMLIN-1•TST786PD1-VEGFGREMLIN-1•TST012FGFR2b•TST105FGFR2bADC•TST013LIV-1ADC MSB0254TST003osemitamab (TST001)osemitamab (TST001)Claudin18.2MSB0254TST003 Osemitamab (TST001)ADCCClaudin18.2 Osemitamab (TST001)Claudin18.2ADCCClaudin18.2(PDAC)osemitamab (TST001)+Claudin18.2PDAC Claudin18.2Claudin18.2III38%Osemitamab(TST001)Claudin18.2ADCCADCCClaudin18.2osemitamab (TST001)~55%osemitamab (TST001)Claudin18.2 2025osemitamab (TST001) •20253Claudin18.2•20256Osemitamab (TST001)CAPOX(TranStar102)IIG#4032)2025ASCO2614G11 IHC LDTCLDN18.240%2+3+PDL1(mOS)21.7(mPFS)16.6(cORR)68%(mDoR)16.5 OSEMITAMAB (TST001)CDx •CDxClaudin18.2(CDx)osemitamab (TST001)Claudin18.2TranStar301III MSB0254VEGFR2 MSB0254VEGFR2MSB0254VEGFR-2VEGFR-2VEGFR-2IRP2DVEGFR2MSB0254 TST003GREMLIN-1 TST003GREMLIN-1FIHTST003PK TST786PD1-VEGFGREMLIN-1 TST786PD1-VEGFGREMLIN-1GREMLIN-1PD1-VEGFPFSOSPFSOS •2025 TST012FGFR2b TST012FGFR2bosemitamab (TST001) TST105ADC TST105FGFR2b(ADC)FGFR2bADC •20254AACRTST105TST105IMMAEADCAACRTST105FGFR2b TST013LIV-1ADC TST013LIV-1ADCLIV-1ADCTOPO-IPKADCADCTST013 blosozumab (TST002)TST004TST008TST801TST808 blosozumab (TST002)IITST801IgASLE1844 Blosozumab (TST002) Blosozumab (TST002)blosozumabIIblosozumab (TST002)(BMD)12blosozumab (TST002)BMD17.7%BMD6.2%32blosozumab (TST002)BMD85BMD1,200 mgblosozumab (TST002)85D85BMD3.52%6.20%BMD1.30%2.24%PK/PDIICTP TST004IgANMASP-2 TST0042(MASP2)TST004IgANMASP2I TST008MASP-2BAFF TST008MASP2B TST801 TST801BAFFTACIBAFFAPRILTACIBBAFFAPRILSLELN IgAN gMGTST801BINDBAFFTST801TST801BdsDNAIgA IgM IgG TST808B TST808BTST808BTST808IgANIND 18A.08(3) ADC osemitamab (TST001)BMSblosozumab (TST002)TST004ADC Osemitamab (TST001) osemitamab (TST001)Claudin18.2PDAC 2022(BMS)osemitamab (TST001)®PD-1Claudin18.2BMS osemitamab (TST001)Claudin18.2Claudin18.2osemitamab(TST001)Claudin18.2osemitamab(TST001)III(TranStar301) Claudin18.2CDxIII(TranStar301) osemitamab (TST001) Blosozumab (TST002) 2019LY-2541546 (blosozumab)LY-3108653 LY-2950913 blosozumab (TST002)GMPTST002 INDIIINDIII blosozumab (TST002) TST004 2020GMPGLPGLP FDAINDTST004 TST003 TST801 TST808TST008 TST105 TST013 osemitamab (TST001)TST003TST005 ADCClaudin18.2 •20253 25CDMOCDMOCDMO •ExcelPro CHOCHOExcelPro CHO siRNAsiRNACDMO CMCCDMO CMC •osemitamab (TST001)FDA Cosemitamab (TST001) ADC •CDMO• CDMO •CDMOCDMO•INDCMCsiRNAsiRNA•• CDMO2025 Osemitamab (TST001) •Claudin18.2osemitamab (TST001)(TranStar301)EMA••Claudin18.2 TST003 •TST003I TST013 •TST013IND TST801 •TST801IND